Clinical Immunoanalyzer Market Introduction
Clinical immunoanalyzer is a diagnostic device used to detect specific analytes in blood or in fluids by employing immunoassay processes such as chemiluminescence immunoassay, enzyme linked fluorescent immunoassay, enzyme linked immunosorbent assay, and radioimmunoassay (RIA). An immunoanalyzer comprises washer, reagent dispenser, auto sampler, and the offered product depending upon the configuration and test options. Few clinical immunoanalyzer products use automated chemical analyser which reduces manual intervention and improves the workflow. These clinical immunoanalyzers are used in hospitals and laboratories for the detection of bacterial infections and viral toxins. These are also used in drug monitoring, allergy testing, as cancer markers and in detecting toxins.
Global Clinical Immunoanalyzer Market: Competitive Landscape
Major players operating in the global clinical immunoanalyzer market include F. Hoffmann-La Roche Ltd., Abbott, Siemens Healthineers, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., bioMérieux SA, Werfen Life, Thermo Fisher Scientific, Inc., Tosoh Corporation, and Randox Laboratories. Strategies adopted by the key players such as mergers & acquisitions, partnerships, joint ventures, and agreements are projected to boost the growth of the global clinical immunoanalyzer market. These players are investing in the development of novel immunoassays in the infectious diseases domain with increasing database on genetics and biomarkers of various infectious pathogens.
Stuck in a Neck-to-Neck Competition with Other Brands? Request a Custom Report on “Clinical Immunoanalyzer Market” here
Bio-Rad Laboratories, Inc.
Bio-Rad Laboratories, Inc. manufactures and supplies a broad range of products for diversified line of life science research and clinical diagnostics. The company is a leader in the life sciences market. It develops, manufactures, and markets approximately 6,000 reagents, apparatus, and laboratory instruments. The instruments portfolio comprises high, medium, and low volume clinical diagnostics such as automated multiplex testing, western blot processing, and others. Its products and systems are utilized to separate complex chemicals and biological materials to identify, analyze, and purify its components. Bio-Rad Laboratories, Inc. has direct distribution in 35 countries, apart from the U.S.
Thermo Fisher Scientific
Founded in 2006, Thermo Fisher Scientific is a global company that engages in the development, manufacture, and commercialization of life sciences products for the health care, pharmaceutical & biotechnology, and life sciences industries. It operates through four segments: specialty diagnostics, analytical instruments, life sciences solutions, and laboratory products & services. The specialty diagnostics segment offers a range of instruments, kits, and reagents for customers in health care, academic institutes, and other service providers. The segment comprises clinical diagnostics, immunodiagnostics, microbiology, and other businesses. Thermo Fisher Scientific offers products and services to more than 400,000 customers across the globe.
bioMérieux SA is a global pioneer in clinical microbiology, offering solutions in two segments; clinical diagnostics and industrial microbiology. The company has a strong distributor network. It provides services in 160 countries, and has presence in around 43 countries. bioMérieux SA has 19 production sites and 20 research & development centers across the globe. The company is a leader in industrial microbiological control and syndrome molecular diagnosis solutions.
Global Clinical Immunoanalyzer Market Dynamics
High Prevalence and Incidence Rates of Chronic and Infectious Diseases to Drive Demand for Clinical Immunoanalyzers
Prevalence of infectious and chronic diseases across the globe drives demand for early diagnosis. Hence, diagnosis of infectious diseases is one of the leading applications of clinical immunoanalyzers. There has been an increase in investment in the development of new assays for diagnosis of various infectious diseases. In April 2017, the U.S. Department of Health and Human Services awarded Siemens Healthineers for the development of Zika virus immunoassay test to be used on its Advia platform of immunoassay analyzers. High prevalence of infectious diseases is projected to drive demand for diagnostic tests. Demand for clinical immunoanalyzers is likely to increase owing to its benefits in monitoring transfusion medicine, such as blood transfusion and organ transplant. Moreover, incidence of endocrinology diseases such as thyroid dysfunction, diabetes mellitus, and also the incidences of osteoporosis is rising owing to changing lifestyles. This is likely to boost demand for clinical immunoanalyzers.
Need an Overview of the Report on Clinical Immunoanalyzer Market? Ask for the Brochure here
Development of New Assays to Expand Application Areas to Boost Market
The increasing knowledge on biomarkers of various chronic diseases has driven industry experts and researchers to apply this information in the development of new assays to expand the applications of automated immunoassay analyzers. Development in the fields of genomics and proteomics has expanded the database of biomarkers used by industry players to develop new assays. For example, a chemiluminescence assay has been developed to test vitamin D deficiency, which was earlier diagnosed through manual ELISA methods. New molecular diagnostic tests are being developed for infectious diseases; however, these tests lack high throughput and short test time features, which make immunoassay analyzers such as ELISA and CLIA the preferred choice. Drug monitoring is another area where automated immunoassay manufacturers are investing to develop new assays that shorten the test time and help in drug monitoring.
Pressure on Laboratories to Reduce Operational & Capital Expenses to Restrain Market
Stringent laws and regulations and decline in reimbursements from the public sector in the developed markets such as the U.S. and countries in Western Europe are inducing independent diagnostic laboratories to reduce capital expenditure. Moreover, factors such as rise in competition and consolidation among hospitals and diagnostic laboratories are anticipated to restrain the market in the near future.
Global Clinical Immunoanalyzer Market Segmentation
Based on technology, the global clinical immunoanalyzer market can be classified into:
- Chemiluminescence Immunoassay (CLIA)
- Enzyme Linked Fluorescent Immunoassay (ELFA)
- Enzyme Linked Immunosorbent Assay (ELISA)
- Radioimmunoassay (RIA)
In terms of application, the global clinical immunoanalyzer market has been categorized into:
- Cancer Markers
- Infectious Diseases
- Cardiac Disease
- Drug Monitoring
Based on end-user, the global clinical immunoanalyzer market has been divided into:
- Diagnostic Laboratories
- Blood Banks
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.